Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`E uivalent of Form PTO/SB/OBa 07-09)
`
`Application Number
`Filing Date
`First Named Inventor
`
`Complete ifKnown
`15/655,078
`July 20, 2017
`Alexandru DEAC
`1629
`TRAN, My-Chau T.
`
`3685.0430001/RC1VI/1VJFG
`
`Attorney Docket Number
`
`U.S. PATENT DOCUMENTS
`
`.
`Number—Kind Code 2 (If
`
`known)
`
`Publication Date
`MM—DD—YYYY
`
`Name of Patentee or
`Applicant of Cited Document
`
`Pages, Columns, Lines, Where
`Relevant Passages or Relevant Figures Appear
`
`Examiner
`initiaIS*
`
`.
`
`C1te
`No.1
`
`("
`
`(‘FFFFFFFFFFFFF‘
`
`("
`
`
`
`
`
`-———
`-———
`-———
`-———
`-———
`-———
`-———
`-———
`-———
`-———
`-———
`-———
`-———
`-———
`
`
`Examiner Signature— Date Considered —
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
`and not considered. Include copy of this form with next communication to applicant.
`1 Applicant’s unique citation designation number (optional). 2 See
`Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent
`document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a
`check mark here if English language Translation is attached.
`
`

`

`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`
`
`Application Number
`Filing Date
`
`Complete ifKnown
`15/655,078
`July 20, 2017
`
`Attorney Docket Number
`
`1629
`TRAN, My-Chau T.
`3685.0430001/RC1VI/1VJFG
`
`E uivalent of Form PTO/SB/OBa 07-09)
`
`
`FOREIGN PATENT DOCUMENTS
`Pages, Columns, Lines,
`Publication
`Date
`MM—DD—YYYY
`
`Foreign Patent Document
`
`Name of Patentee or
`Applicant of Cited Document
`
`Examiner
`initia1s*
`
`Cite
`No.1
`
`country C0de3—Number4—Kind
`Code5 (if known)
`wo 2010/134074 A1
`wo 2011/056240A2
`wo 2012/079072 A2
`
`Where Relevant Passages
`or Relevant Figures
`Appear
`Neurodcrm Ltd. —
`11-25-2010
`05-12-2011——
`06-14-2012
`Synagile Corporation —
`2:::::;:°;.1:rrwhW —
`————
`————
`————
`————
`————
`————
`————
`————
`————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`-————
`
`
`
`
`
`
`l34436l3il.docx
`
`Examiner Signature— Date Considered —
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
`and not considered. Include copy of this form with next communication to applicant.
`1 Applicant’s unique citation designation number (optional). 2 See
`Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent
`document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a
`check mark here if English language Translation is attached.
`
`

`

`Substitute for form 1449/PTO
`
`Complete ifKnown
`
`E uivalent of Form PTO/SB/08b
`
`-09)
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`NON PATENT LITERATURE DOCUMENTS
`
`Examiner
`Initials"<
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when
`appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.),
`date, page(s), volume-issue number(s), publisher, city and/or country where published
`
`
`
`
`
`
`
`
`
`AGIN, P.P. et al., “Phosphorylated Mixed Isomers of L-Dopa Increase Melanin Content
`in Skins of Skh-2 Pigmented Hairless Mice,” Pigment Cell Res. 1:137-142, Alan R.
`Liss, Inc. (1987)
`
`DHARESHWAR, SS. and STELLA, V.J., “Your Prodrug Releases Formaldehyde:
`Should You Be Concerned? No!,” J. Pharm. Sci. 97:4184-4193, American
`Pharmaceutical Association (2008)
`
`MAEDA, H. et al., “Phosphonylation of L-Dopa with Sodium Diphosphonate in
`Aqueous Solution,” Phosphorus Res. Bull. 25 :56-60, Japanese Association of Inorganic
`Phosphorus Chemistry (2011)
`
`International Search Report dated 9 February 2016 issued in PCT Patent Application
`No. PCT/US2015/056686
`
`International Preliminary Report on Patentability dated 25 April 2017 issued in PCT
`Patent Application No. PCT/US2015/056686
`
`International Search Report dated 18 April 2016 issued in PCT Patent Application No.
`PCT/US2016/014005
`
`International Preliminary Report on Patentability dated 25 July 2017 issued1n PCT
`Patent A lication No. PCT/US2016/014005
`
`International Search Report dated 20 October 2017 issued1n PCT Patent Application
`No. PCT/US2017/043103
`
`International Preliminary Report on Patentability dated 22 January 2019 issued1n PCT
`Patent Application No. PCT/US2017/043103
`
`KEARNEY, AS. and STELLA, V.J., “The in Vilro Enzymic Labilities of Chemically
`Distinct Phosphomonoester Prodrugs,” Pharm. Res. 9:497 -503, Plenum Publishing
`Corporation (1992)
`
`PAWELEK, J .M. and MURRAY, M., “Increase in Melanin Formation and Promotion
`of Cytotoxicity in Cultured Melanoma Cells Caused by Phosphorylated Isomers of
`
`L-Dopa,” Cancer Res. 46:493-497, American Association for Cancer Research (1986)
`
`SAFADI, M. et al., “Phosphoryloxymethyl Carbamates and Carbonates-Novel Water-
`Soluble Prodrugs for Amines and Hindered Alcohols,” Pharm. Res. 10:1350-1355,
`Plenum Publishing Corporation (1993)
`
`ZHU, Z. et al., “Phosphate Prodrugs of PD154075,” Bioorg. Med. Chem. Lett. 10:1121-
`1124, ElseVier Science Ltd. (2000)
`
`\PL9
`
`Examiner
`
`Signature
`
`Date
`
`Considered
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
`and not considered. Include copy of this form with next communication to applicant.
`1 Applicant’s unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
`
`

`

`Substitute for form 1449/PTO
`
`Complete ifKnown
`
`E uivalent of Form PTO/SB/08b
`
`-09)
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`July 20, 2017
`Alexandru DEAC
`1629
`_XaminerName—TRAN, My--Chau T
`
`—--_ Attorney Docket Number
`36850430001/RCWMFG
`
`December 5, 2018 (NOT PUBLISHED)
`
`GIACOMONI, P.U., “Sun Protection in Man,” Comprehensive Series in
`Photosciences 3 :642-648, ElseVier Science B.V. (2001)
`
`Co-pending U. S. Application No. 15/491,642, inventors Cardinal-David et al., filed on
`April 19, 2017 (NOT PUBLISHED)
`
`Co-pending US. Application No. 16/210,996,
`
`inventors Cardinal-David et al., filed on
`
`1344372371.d0cx
`
`Examiner
`
`Signature
`
`Date
`
`Considered
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
`and not considered. Include copy of this form with next communication to applicant.
`1 Applicant’s unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
`
`